AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Complete Genomics Partners with Eurofins Clinical Enterprise to Expand Sequencing Service Offerings

NeuroKaire Secures $10M to Transform Precision Medicine in Psychiatry and Neurology

Home
/
med-marvels
/
details

Leukemia Survivor Embraces New Lease of Life Through CAR T-Cell Therapy at Apollo Cancer Centre

NextEdge Admin

08 Jun 2024

1 min 36 sec

In a groundbreaking medical achievement for Gujarat, the Apollo Cancer Centre (ACC) in Ahmedabad successfully conducted Chimeric Antigen Receptor (CAR) T-cell therapy on a 48-year-old woman with relapsed acute lymphoblastic leukemia, alongside complex co-morbidities.

“Performing CAR T-cell therapy in such a challenging scenario, compounded by the patient’s existing health conditions, required exceptional expertise,” explained Lt Gen Dr Velu Nair, the Head & Chief Consultant of Haemato-Oncology & Bone Marrow Transplant at Apollo Cancer Centre, Ahmedabad.

Having previously undergone an allogenic bone marrow transplant, the patient achieved molecular remission post-immunotherapy, paving the way for CAR T-cell therapy.

“This case represents a significant milestone in Gujarat’s medical landscape and signifies a major leap forward in treating relapsed acute lymphoblastic leukemia,” remarked Dr Nair.

Neeraj Lal, the COO and Unit Head of Apollo Cancer Centre in the Gujarat Region, emphasized, “The success of the CAR T-cell therapy underscores our unwavering dedication to offering state-of-the-art treatments and underscores our capacity to manage intricate medical conditions.”